BioSpace News Archive

Hilltop BioSciences, a veterinary biotech company pioneering the development of innovative regenerative therapies, will be introducing several new formulations at VMX in Orlando where they will be showcased in the Startup Circle (Booth s5027).

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at PepTalk occurring January 16-22, 2023 in San Diego, CA.

First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway.

ConcertAI, LLC (ConcertAI), a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence (RWE) solutions for life sciences and healthcare, presented at the JP Morgan Healthcare Conference (JPM) today.

Digital health startup CARI Health has closed an oversubscribed $2.3 million seed round that will help it bring the world’s first wearable real-time medication monitor to market.

Medical Home Network (MHN) today announced its risk stratification model, which incorporates social determinants of health (SDOH) and uses AI, can more accurately identify high- and rising-risk members than traditional models, according to new research published in the peer-reviewed American Journal of Managed Care.

iSpecimen Inc., an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately.

Bio4t2 dosed the first patient with T cells bearing a chimeric antigen receptor (CAR) that targets overexpression of BT-001 antigen present on various types of solid tumors.

Iridex Corporation today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended December 31, 2022.

ProKidney Corp. today announced the publication of the trial design and early data analysis from REGEN-003, a Phase 2 clinical study of Renal Autologous Cell Therapy (REACT ® ), in the Journal of Blood Purification.